MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$30,000K
Proceeds from issuance of
common stock under open...
$20,233K
Proceeds from maturities
of investments
$3,200K
Net cash provided by
financing activities
$49,802K
Net cash provided by
investing activities
$3,200K
Effect of exchange
rates on cash, cash...
$2K
Canceled cashflow
$431K
Net increase
(decrease) in cash, cash...
$30,276K
Canceled cashflow
$22,728K
Payment of equity
issuance costs
$431K
Interest expense added to
debt principal
$6,911K
Stock-based compensation
expense
$3,007K
Accounts receivable, net
-$2,821K
Amortization of debt issuance
costs and discounts
$2,362K
Prepaid expenses and
other assets
-$659K
Inventory
-$439K
Accounts payable
$276K
Operating lease
right-of-use assets
-$139K
Depreciation
$12K
Net amortization of
premiums and discounts on...
-$2K
Net cash used in
operating activities
-$22,728K
Canceled cashflow
$16,628K
Net loss
-$22,392K
Change in fair value of
embedded derivatives and...
$16,481K
Accrued expenses and
other liabilities
-$257K
Operating lease
liabilities
-$226K
Back
Back
Cash Flow
source: myfinsight.com
Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (KPTI)